InvestSMART

Emyria Limited (ASX: EMD) - Announcements

Current share price for EMD : $0.047 0.001 (2.17%)+

ASX company news and announcements for Emyria Limited (EMD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Emyria Limited (EMD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Emyria Limited (EMD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Emyria Limited (EMD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$38 Preclinical studies initiated for MDMA-inspired analogues 4 Aug 2022 9:54AM $0.215 $0.047 fallen by 78.14%
$38 Appendix 4C - Quarterly 28 Jul 2022 11:24AM $0.215 $0.047 fallen by 78.14%
$38 Emyria expands drug candidate library inspired by MDMA 18 Jul 2022 8:19AM $0.220 $0.047 fallen by 78.64%
$38 Notification regarding unquoted securities - EMD 9 Jun 2022 9:21AM $0.250 $0.047 fallen by 81.20%
$38 Drug development webinar presentation 1 Jun 2022 5:23PM $0.275 $0.047 fallen by 82.91%
$38 Emyria expands MDMA analogue program with UWA 31 May 2022 9:45AM $0.270 $0.047 fallen by 82.59%
$38 Emyria Investor Webinar, June 1st 30 May 2022 12:56PM $0.275 $0.047 fallen by 82.91%
$38 EMD-RX5 demonstrates excellent safety and bioavailability 25 May 2022 9:30AM $0.300 $0.047 fallen by 84.33%
$38 Trading Halt 23 May 2022 9:08AM $0.300 $0.047 fallen by 84.33%
$38 Further positive MDMA analogue screening results received 10 May 2022 8:38AM $0.250 $0.047 fallen by 81.20%
$38 Appendix 4C - Quarterly 27 Apr 2022 9:44AM $0.305 $0.047 fallen by 84.59%
$38 Results of Meeting 20 Apr 2022 1:22PM $0.340 $0.047 fallen by 86.18%
$38 Change of Director's Interest Notice MW 20 Apr 2022 9:28AM $0.330 $0.047 fallen by 85.76%
$38 EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial 14 Apr 2022 9:47AM $0.305 $0.047 fallen by 84.59%
$38 Clinitrials to lead multi-site Phase 3 trial for EMD-RX5 13 Apr 2022 9:22AM $0.300 $0.047 fallen by 84.33%
$38 Dosing Commences For EMD-RX5 Phase 1 Human Clinical Trial 7 Apr 2022 9:45AM $0.310 $0.047 fallen by 84.84%
$38 Broker Briefing Presentation 24 Mar 2022 3:09PM $0.330 $0.047 fallen by 85.76%
$38 Emyria to present webinar, March 24th 23 Mar 2022 9:32AM $0.345 $0.047 fallen by 86.38%
$38 Letter to Shareholders - Adjourned General Meeting 18 Mar 2022 6:19PM $0.325 $0.047 fallen by 85.54%
$38 Addendum to Notice of Meeting and Proxy Form 18 Mar 2022 6:16PM $0.325 $0.047 fallen by 85.54%
$38 Emyria launches second ultra-pure CBD capsule 17 Mar 2022 10:32AM $0.300 $0.047 fallen by 84.33%
$38 EMD-RX5 program advancing Phase 1 clinical trials underway 17 Mar 2022 9:58AM $0.280 $0.047 fallen by 83.21%
$38 Recruitment commenced for EMD-RX5 Phase 1 Study 9 Mar 2022 9:47AM $0.275 $0.047 fallen by 82.91%
$38 Hidden Gems Webinar Presentation 4 Mar 2022 10:26AM $0.330 $0.047 fallen by 85.76%
$38 Ethics approval received for EMD-RX5 Phase 1 Study 3 Mar 2022 1:41PM $0.325 $0.047 fallen by 85.54%

326 - 350 of 553 results

Page 14 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.